Covestor
ORMP icon

Covestor’s Oramed Pharmaceuticals ORMP Stock Holding History

Covestor’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2K Buy
+388
New +$1.75K ﹤0.01% 1985

Other funds holding ORMP

Aquamarine Financial
Aquamarine Financial George Town $1.94B AUM 47.01% 1-Year Est. Return
Murchinson
Murchinson Toronto, Ontario, Canada $908M AUM 36.04% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $144M AUM 109.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Rathbones Group
Rathbones Group Liverpool, United Kingdom $28B AUM 17.3% 1-Year Est. Return

Covestor's ORMP Position: Q3 2026 in Review

Covestor opened a new position in Oramed Pharmaceuticals (ORMP) in Q3 2026: 388 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1985 among its holdings.

66 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Covestor held 388 shares of Oramed Pharmaceuticals worth $2K as of Q3 2026.
  • Oramed Pharmaceuticals was a new Covestor position in Q3 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #1985 holding.
  • 66 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.